iNOS as a therapeutic target for treatment of human tumors

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Nitric oxide synthase (NOS) is overexpressed in various human tumors compared to normal tissues.
• This overexpression presents a potential therapeutic target for novel anticancer strategies.
• Understanding NOS expression levels is crucial for effective tumor profiling and treatment selection.

Purpose of the Study:

• To explore the potential of nitric oxide synthase (NOS) as a target in anticancer therapies.
• To review strategies for modulating NOS activity or leveraging its functions for cancer treatment.
• To provide evidence for exploiting NOS in tumor profiling and therapeutic interventions.

Main Methods:

• Profiling tumors to identify high NOS expression levels.
• Modulating endogenous NOS levels through induction or gene therapy.
• Utilizing the reductase domain of NOS to activate bioreductive drugs like AQ4N.
• Leveraging nitric oxide production to sensitize hypoxic tumor cells to radiation.
• Inhibiting Hypoxia-Inducible Factor 1 (HIF-1) to enhance nitric oxide-based therapies.

Main Results:

• The reductase domain of NOS can be exploited to activate bioreductive drugs.
• Nitric oxide production can increase the sensitivity of resistant hypoxic cells to radiation.
• Inhibition of HIF-1 can amplify nitric oxide-based therapeutic approaches.
• Evidence supports multiple routes for exploiting NOS in cancer treatment.

Conclusions:

• Nitric oxide synthase (NOS) offers multiple exploitable avenues for anticancer therapies.
• Strategies involving bioreductive drug activation, enhanced radiation sensitivity, and HIF-1 inhibition show promise.
• Targeting NOS represents a significant opportunity for developing innovative cancer treatments.